20.2 C
New York

Novavax 2022 Covid vaccine deliveries off to slow start



Reuters | May 9 | Updated on: May 10, 2022

It plans to conduct a late-stage study to test its vaccine in children aged 5-11 by the third quarter.

Novavax Inc on Monday revealed a sharp drop in its Covid-19 research funding for the first quarter and said it shipped less than a fourth of the total planned Covid vaccine deliveries for 2022.

Shares of the company were down nearly 8% after the bell.

Novavax has delivered 31 million doses of its vaccine against Covid-19, a small fraction of the 2 billion shots it plans to send around the world in 2022.

It also posted a near 78% drop in grant revenue to $99 million from the U.S. government and the Coalition for Epidemic Preparedness Innovations.

Sales of Novavax’s recombinant protein vaccine, NVX-CoV2373, brought in $586 million in the quarter ended March 31, while the company earned $19 million through royalties and adjuvant sales to its licensing partners including Serum Institute of India.

Despite the slow start to Covid-19 vaccine deliveries for the year, Novavax said it continues to forecast total revenue of $4 billion to $5 billion for 2022.

The company also said it plans to initiate a late-stage study to test its vaccine in children aged 5 to 11 years by the third quarter.

Published on May 10, 2022

You May Also Like

Recommended for you

Related articles

Recent articles